Gara Jalqabaatti › Non-Hodgkin Lymphoma › Texas › Houston
Qorannoo klinikaalii Non-Hodgkin Lymphoma Houston, TX keessatti
Qorannoo 31 Non-Hodgkin Lymphoma f Houston fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Md Anderson Cancer Center, Houston
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Namoota walitti qabaa jiraSadarkaa 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Namoota walitti qabaa jiraSadarkaa 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Namoota walitti qabaa jiraSadarkaa 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Namoota walitti qabaa jiraQorannoo ilaalaa
- Texas Children's Hospital, Houston
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Namoota walitti qabaa jiraSadarkaa 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Namoota walitti qabaa jiraSadarkaa 1
- Baylor College of Medicine, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Md Anderson Cancer Center, Houston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Namoota walitti qabaa jiraSadarkaa 2
- Research Site, Houston
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Namoota walitti qabaa jiraSadarkaa 1
- Clinical Trial Site, Houston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Namoota walitti qabaa jiraSadarkaa 3
- MD Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
Namoota walitti qabaa jiraSadarkaa 2
- M D Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
Namoota walitti qabaa jiraSadarkaa 2
- The University of Texas MD Anderson Cancer Center, Houston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Namoota walitti qabaa jiraQorannoo ilaalaa
- M.D. Anderson Cancer Center, Houston
- Texas Children's Hospital - Baylor Medical Center, Houston
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
Namoota walitti qabaa jiraSadarkaa 1
- Harris Health System - Ben Taub General Hospital/Smith Clinic, Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
- fi 1 dabalataa
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Namoota walitti qabaa jiraSadarkaa 2
- M D Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Namoota walitti qabaa jiraSadarkaa 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Namoota walitti qabaa jiraSadarkaa 1
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Namoota walitti qabaa jiraSadarkaa 4
- University of Texas MD Anderson Cancer Center, Houston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Namoota walitti qabaa jiraSadarkaa 4
- University of Texas MD Anderson Cancer Center, Houston
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Namoota walitti qabaa jiraSadarkaa 1
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Namoota walitti qabaa jiraSadarkaa 2
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Texas MD Anderson Cancer Center, Houston
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
Qorannoo Non-Hodgkin Lymphoma magaalota biroo keessatti
- New York City, NYQorannoo 31
- Boston, MAQorannoo 26
- Nashville, TNQorannoo 21
- Philadelphia, PAQorannoo 20
- Baldwin Park, CAQorannoo 19
- Washington, DCQorannoo 18
- Chicago, ILQorannoo 18
- Atlanta, GAQorannoo 18
- Milwaukee, WIQorannoo 18
- Columbus, OHQorannoo 18
- Dallas, TXQorannoo 17
- Seattle, WAQorannoo 16
Qorannoo biroo Houston keessatti
- Kansara Qara'a Non-Small CellQorannoo 145
- Saree OljooQorannoo 126
- Saree (Gosoota Hunda)Qorannoo 121
- Kansara MetastatikiiQorannoo 104
- Kansarii ColorectalQorannoo 102
- Kansarii OvariiQorannoo 89
- Leukemia Myeloidii HamaaQorannoo 85
- Dhibee QaraQorannoo 78
- Kansarii ProstateQorannoo 76
- Kansa EndometiriyaaliiQorannoo 68
- Kansarii PancreasQorannoo 61
- MelanomaQorannoo 59
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.